HomeAbout

TL;DR CNBC


Eli Lilly beats on quarterly profit, hikes full-year guidance on strong sales of Zepbound, Mounjaro - TL;DR CNBC

Eli Lilly beats on quarterly profit, hikes full-year guidance on strong sales of Zepbound, Mounjaro

Publishing timestamp: 2024-04-30 11:04:23


Summary

Eli Lilly reported strong first-quarter results, with adjusted profit beating expectations. The company hiked its full-year guidance due to strong sales of its diabetes drug Mounjaro and weight loss treatment Zepbound. The company expects significant production increases in the second half of the year. Despite some sales missing expectations, Eli Lilly's stock jumped more than 5% on the news.


Sentiment: POSITIVE

Tickers: LLY

Keywords: businesseli lilly and cobusiness newsbreaking newspharmaceuticalsunited statesdavid a. rickshealth care industrybiotech and pharmaceuticalsearningsbiotechnology

Source: https://www.cnbc.com/2024/04/30/eli-lilly-lly-earnings-q1-2024.html


Developed by Leo Phan